Latest Conference Articles

Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.

Intensivists gathered at the CHEST 2025 Annual Meeting to discuss how climate change is affecting and will affect their practice of treating pulmonary conditions.

Rebecca Dent, MD, MSc, of the National Cancer Center in Singapore, gives insights on the use of antibody-drug conjugates (ADCs) in early breast cancer treatment.

Results from the ASPEN trial also show that brensocatib displayed several benefits when used in patients with bronchiectasis, including a reduction in symptom burden.

New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements vs placebo.

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without sacrificing quality of life in prostate cancer.

Experts at ESMO Congress highlighted the urgent need for open discussions on sexual health post cancer treatment, emphasizing its impact on quality of life.

Combination therapy with enfortumab vedotin and pembrolizumab significantly reduces progression and mortality risk of muscle invasive bladder cancer in first-line treatment.

Colorblind energy devices and long-wavelength lasers are safest for darker skin, says Ariella Kauvar, MD, with a thorough patient history and physical exam key to preventing complications.

Adjuvant abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy prolonged survival in high-risk HR-positive, HER2-negative early-stage breast cancer.

Panels at the conference include coverage of new guidelines, the use of AI in pulmonary care, and progress on respiratory vaccines.

Results presented at ESMO show zongertinib produced 79% PFS at 6 months and nearly half of patients remained on treatment at the data cutoff. Investigators reported strong efficacy and tolerability in first-line treatment of advanced HER2-mutant NSCLC.

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS.

Arielle Kauvar, MD, says pre- and post-treatment care helps prevent hyperpigmentation and complications from laser procedures for all skin types, including skin of color.

Patients beginning their cancer journeys should advocate for themselves and use support groups to help navigate survivorship challenges.

ESMO Congress 2025 in Berlin showcases breakthroughs in precision medicine for bladder, breast, lung, and prostate cancers, enhancing patient quality of life.

ACOs serving patients with complex needs are on the rise, but policy changes are needed to support providers treating special populations.

Payer contracts should incentivize the delivery of comprehensive, total-person cancer care, says Brian Mulherin, MD.

Experts discussed safe and effective management strategies for patients with hidradenitis suppurativa at the 2025 Skin of Color Update.

Vivek Subbiah, MD, highlights key topics at the 50th European Society for Medical Oncology (ESMO) Congress, including the rise of tumor-agnostic therapies and the use of artificial intelligence (AI) in cancer care.

Many cancer survivors face ongoing physical and mental health challenges, which peer support and online resources can help address, says Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd.

Despite systemic challenges, oncology practices use value-based care, community partnerships, and clinical trials to improve patient access and outcomes, says Brian Mulherin, MD.

Jenifer Soung, MD, fo Southern California Dermatology, discussed how glucagon-like peptide-1 receptor agonists aid in treating patients with psoriatic disease.

Some comorbidities associated with psoriatic disease can be treated with GLP-1 RAs and multidisciplinary care.

Eliot F. Battle, MD, a dermatologist, reflects on how he chooses the right treatments for patients with skin of color.

Tiffany Mayo, MD, speaks on emerging therapies for treating hidradenitis suppurativa at the 2025 Skin of Color Update.

Vivek Subbiah, MD, says artificial intelligence (AI) should assist clinicians in precision oncology, not replace human decision-making.

Tiffany Mayo, MD, discusses the emerging therapy landscape for treating patients with hidradenitis suppurativa.

Artificial intelligence, automation, and expanded pharmacist roles help reduce administrative burdens, improve workflow, and support providers in delivering cancer care, according to Scott Soefje, PharmD, MBA, BCOP.